Axitinib in the treatment of metastatic renal cell carcinoma

Thai H Ho, Eric Jonasch

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Axitinib, an oral small-molecule tyrosine kinase inhibitor targeted to angiogenesis, has demonstrated activity in advanced renal cell carcinoma. Common side effects include hypertension, fatigue and dysphonia. Axitinib is currently awaiting approval as a second-line agent in the treatment of advanced renal cell carcinoma. Trials, which include treatment-naive patients, are ongoing and will study the benefit of axitinib in the first-line setting.

Original languageEnglish (US)
Pages (from-to)1247-1253
Number of pages7
JournalFuture Oncology
Volume7
Issue number11
DOIs
StatePublished - Nov 2011
Externally publishedYes

    Fingerprint

Keywords

  • AG 013736
  • angiogenesis
  • AXIS
  • axitinib
  • renal cell carcinoma
  • targeted therapy
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this